Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | WNT1 | P04628 | 3/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18216498 | 1.00 | NPC1 (0.56) | NPC1RAB9ACSNK2A1EPHB3SMYD3 | |
| SCHEMBL20185026 | 0.93 | DYRK1A (0.54) | DYRK1AHPGDWNT1NTRK1ALOX15 | |
| SCHEMBL18216206 | 0.93 | DYRK1A (0.54) | DYRK1AHPGDWNT1NTRK1ALOX15 | |
| SCHEMBL18216497 | 0.83 | HPGD (0.51) | NPC1RAB9ASMYD3HPGDSMN1; SMN2 | |
| SCHEMBL20185024 | 0.83 | HPGD (0.51) | NPC1RAB9ASMYD3HPGDSMN1; SMN2 | |
| SCHEMBL18216507 | 0.80 | ALDH1A1 (0.52) | HPGDSMN1; SMN2 | |
| SCHEMBL20184965 | 0.80 | ALDH1A1 (0.52) | HPGDSMN1; SMN2 | |
| SCHEMBL20201142 | 0.78 | HPGD (0.49) | HPGDALOX15SMN1; SMN2 | |
| SCHEMBL18216438 | 0.77 | HPGD (0.55) | NPC1RAB9AHPGDALOX15 | |
| SCHEMBL20185001 | 0.76 | HPGD (0.45) | RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | claimed |
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | C1R, C9, C1S | NPC1 558/4885RAB9A 77/4885CSNK2A1 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.